Evidence map›Paper›PMID 34714583›Full record

ArticleClinical & experimental ophthalmology2022

Biopsy for molecular risk stratification in uveal melanoma: Yields and molecular characteristics in 119 patients.

Vivian Lin, In Young Chung, Elsa Toumi, Daniel McKay, John McKenzie, Penny McKelvie, Farida Zabih, Alexandra Hoffmeister, Dale Wright, Aphrodite Ntzaferi and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Vivian LinSchool of Medical Sciences, Faculty of Medicine, UNSW, Sydney, Australia.ORCID 0000-0003-2300-826X
In Young ChungRoyal Victorian Eye & Ear Hospital, Melbourne, Australia.ORCID 0000-0003-0671-244X
Elsa ToumiDepartment of Anatomical Pathology and Molecular Oncology, SydPath, St Vincent's Hospital Sydney, Sydney, Australia.
Daniel McKayRoyal Victorian Eye & Ear Hospital, Melbourne, Australia.
John McKenzieRoyal Victorian Eye & Ear Hospital, Melbourne, Australia.
Penny McKelvieDepartment of Anatomical Pathology, St Vincent's Hospital Melbourne, Melbourne, Australia.
Farida ZabihDepartment of Cancer Genetics, SydPath, St Vincent's Hospital, Sydney, Australia.
Alexandra HoffmeisterDepartment of Cancer Genetics, SydPath, St Vincent's Hospital, Sydney, Australia.
Dale WrightDepartment of Cytogenetics, Children's Hospital Westmead, Westmead, Australia.
Aphrodite NtzaferiDepartment of Cancer Genetics, SydPath, St Vincent's Hospital, Sydney, Australia.
Iris Junhong WuDepartment of Cancer Genetics, SydPath, St Vincent's Hospital, Sydney, Australia.
Luke HessonKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, Australia.
Adrian FungWestmead and Central Clinical Schools, Specialty of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Li-Anne LimChatswood Private Hospital, Chatswood, Australia.ORCID 0000-0002-6943-1488
Stephen WongDepartment of Anatomical Pathology and Molecular Oncology, SydPath, St Vincent's Hospital Sydney, Sydney, Australia.
Andrew FieldDepartment of Anatomical Pathology and Molecular Oncology, SydPath, St Vincent's Hospital Sydney, Sydney, Australia.
Peter EarlsDepartment of Anatomical Pathology and Molecular Oncology, SydPath, St Vincent's Hospital Sydney, Sydney, Australia.
Michael GiblinChatswood Private Hospital, Chatswood, Australia.
Robert Max ConwayWestmead and Central Clinical Schools, Specialty of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Svetlana CherepanoffDepartment of Anatomical Pathology and Molecular Oncology, SydPath, St Vincent's Hospital Sydney, Sydney, Australia.
St Vincent's Hospital Melbourne · AUSt Vincent's Hospital Sydney · AUThe Royal Victorian Eye & Ear Hospital · AUThe University of Sydney · AUSydney Hospital · AUGarvan Institute of Medical Research · AUUNSW Sydney · AU

Funding

Royal College of Pathologists of Australasia
6 · The paper itself

Abstract

backgroundPrognostic cytological and molecular features of uveal melanoma have been well researched and are essential in management. Samples can be obtained in vivo through fine needle aspirate biopsy, vitrector cutter, forceps or post-enucleation for off-site testing. This study aims to examine cytological and chromosome microarray yields of these samples.

methodsA retrospective cohort analysis of 119 uveal melanoma biopsies submitted to our laboratory. Samples included those taken in vivo (n = 57) and post-enucleation (n = 62). Patient and tumour features were collected including age, sex, primary tumour location, basal diameter and tumour height. Prognostic outcomes measured include cell morphology, chromosomal status and immunohistochemistry.

resultsPost-enucleation biopsies accounted for just over half of our samples (52%). Post-enucleation samples had a more successful genetic yield than in vivo biopsies (77% vs. 50%, p = 0.04) though there was no difference for cytological yields. There was no difference in cytological or microarray yields between instruments. The vitrector biopsy group had the smallest tumour thickness (5 mm vs. 10 mm [fine-needle aspirate biopsy], p = 0.003). There was a strong correlation between monosomy 3, BAP1 aberrancy and epithelioid cell type in post-enucleation samples (T

conclusionsAll three biopsy instruments provide similar cytological yields as post-enucleation sampling, although post-enucleation samples had a more successful chromosome microarray yield. Epithelioid cytomorphology alone is insufficient for prognostication in in vivo biopsies, immunohistochemistry would be a useful surrogate test.

Indexed as

Uveal NeoplasmsBiopsy, Fine-NeedleHumansMelanomaMonosomyPrognosisRetrospective StudiesRisk AssessmentUveal MelanomabiopsycytopathologyFNABgeneticsuveal melanoma

Identifiers

PMID34714583
OpenAlexW3208056747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.